« previous next »
Pages: [1]

Author Topic: Zinbryta (daclizumab) pulled from market due to safety concerns  (Read 284 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9842
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) DRESS syndrome and daclizumab failure--were dangerous signs missed in clinical trials?
« on: July 18, 2018, 11:19:19 am »
More on the failure of Zinbryta--from PubMed, July 18, 2018--DRESS syndrome and daclizumab failure--Were potentially dangerous signs missed in clinical trials?":


https://www.ncbi.nlm.nih.gov/pubmed/30013311




DRESS syndrome = drug reaction with eosinophilia and systemic symptoms


This case history (see link below) goes into more detail about DRESS syndrome--appearing in Neurology (September 1, 2018) under the title "Drug reaction with eosinophilia after daclizumab therapy in MS":


http://nn.neurology.org/content/5/5/e479








« Last Edit: July 18, 2018, 11:20:56 am by agate »
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20 - 3/16/24.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
96 Views 		Last post May 31, 2016, 01:48:51 pm
by agate
0 Replies
209 Views 		Last post July 11, 2017, 03:01:11 pm
by agate
0 Replies
37 Views 		Last post May 17, 2021, 09:17:00 pm
by agate
0 Replies
18 Views 		Last post February 19, 2023, 09:43:41 pm
by agate
0 Replies
5 Views 		Last post February 01, 2024, 10:13:30 am
by agate